Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score 50

CONCLUSION: Pembrolizumab provides a durable, clinically meaningful long-term OS benefit versus chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.PMID:33872070 | DOI:10.1200/JCO.21.00174

Source: Clinical Lung Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Martin Reck Delvys Rodr íguez-Abreu Andrew G Robinson Rina Hui Tibor Cs őszi Andrea F ülöp Maya Gottfried Nir Peled Ali Tafreshi Sinead Cuffe Mary O'Brien Suman Rao Katsuyuki Hotta Ticiana A Leal Jonathan W Riess Erin Jensen Bin Zhao M Catherine Pieta Source Type: research